China Shineway Pharmaceutical Group Limited reported that its authorized share capital as of 31 January 2026 remained at 5,000,000,000 ordinary shares, each with a par value of HKD 0.1, totaling HKD 500,000,000. No changes occurred during the reporting period.

The number of issued shares stayed unchanged at 827,000,000, and there were no treasury shares. The company confirmed that the 25% minimum public float requirement had been met. No movements were recorded under share options, warrants, convertibles, or other share issuance agreements during the month.

The filing was submitted on 6 February 2026 and states that all relevant regulatory requirements were complied with, and no new share issuances or redemptions were carried out.